Health topic

Hospital-acquired infections (HAI)

In developed and developing countries, 7-10% of hospitalized patients will acquire an HAI.1

Rapid diagnostic techniques, like the cobas® MRSA/SA Test, enable the early detection of methicillin-resistant Staphylococcus aureus (MRSA) in colonized patients, supporting the timely implementation of appropriate barrier precautions.

Reliable surveillance programs that quickly and accurately detect colonized patients can help reduce the worldwide burden and spread of these costly, and potentially deadly infections.

Roche offers a broad portfolio of assays and systems to support the detection of hospital-acquired infections.

Related news

Roche expands cobas® Liat® PCR System menu with launch of cobas® MRSA/SA test to target healthcare-associated infections

June 30, 2017

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the CE-IVD launch of the cobas® MRSA/SA nucleic acid test for use on the cobas® Liat® System for the qualitative detection and differentiation of methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA) at the point of care.


Roche launches cobas® Liat® PCR System with four assays into CE-markets

April 3, 2017

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of the cobas® Liat® PCR System with four assays including first 20 minute real-time PCR nucleic acid test to detect Clostridium difficile (C. diff).


Roche receives FDA clearance for the cobas® Cdiff Test to detect Clostridium difficile

May 26, 2015

New test expands menu for healthcare associated infections testing on the widely adopted cobas® 4800 System


Roche receives FDA clearance for next generation cobas® MRSA/SA Test

January 26, 2015

New test detects MRSA and SA, the leading causes of healthcare-associated infections worldwide


Roche launches the cobas® Cdiff Test for detection of Clostridium difficile in markets accepting the CE Mark

March 19, 2014

New test expands menu for hospital-acquired infections testing on the cobas® 4800 System.


Roche announces launch of cobas® MRSA/SA Test in markets accepting the CE mark

January 8, 2014

New test detects methicillin-resistant Staphylococcus aureus and Staphylococcus aureus, the leading causes of healthcare acquired infections worldwide.


FDA clears Roche’s LightCycler® MRSA Advanced Test for use in the U.S.

July 8, 2010

Easy-to-use molecular test offers faster results to help healthcare facilities control spread of methicillin-resistant Staphylococcus aureus (MRSA)


Roche to introduce new LightCycler® MRSA Advanced Test in the EU

April 2, 2009

New test for detection of methicillin-resistant Staphylococcus aureus for better patient care




  1. World Health Organization (WHO). Health care-associated infections Fact Sheet. Accessed May 11, 2016.
Found 0 results in